Martin Schlumberger
8PUBLICATIONS
68CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (8)
Sort by Publication Date:
|Aug 03, 2023
D898_E901 RET Deletion Is Oncogenic, Responds to Selpercatinib, and Treatment Resistance Can Arise Via RET-Independent Mechanisms.Tommaso Porcelli, Marialuisa Moccia, Maria Angela De Stefano
|Apr 19, 2023
A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer.Sophie Leboulleux, Christine Do Cao, Slimane Zerdoud
|May 07, 2021
Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer.Lori J Wirth, Marcia S Brose, Eric J Sherman
|Feb 19, 2021
The importance of the RET gene in thyroid cancer and therapeutic implications.Domenico Salvatore, Massimo Santoro, Martin Schlumberger
|Dec 19, 2020
Current practice in patients with differentiated thyroid cancer.Martin Schlumberger, Sophie Leboulleux
Pageof 2
Frequent Collaborators
3 joint publications
Domenico Salvatore
2 joint publications
Massimo Santoro
2 joint publications
Lori Wirth
1 joint publications
Marcia S Brose
1 joint publications
Eric J Sherman
1 joint publications
Lisa Licitra
1 joint publications
Steven I Sherman
1 joint publications
Keith C Bible
1 joint publications
Christelle De La Fouchardiere
1 joint publications
Ran Xie